文献速递其他结缔组织病血管炎

内皮素受体拮抗剂与磷酸二酯酶-5抑制剂对系统性硬化指端溃疡患者肺动脉高压及硬皮病肾危象发生率的影响

The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于西班牙硬皮病注册库(RESCLE)的回顾性队列研究,纳入544例系统性硬化伴指端溃疡患者,其中221例接受ERAs/PDE5i治疗、323例未治疗。两组肺动脉高压(PAH)和硬皮病肾危象(SRC)发生率差异无统计学意义,但治疗组从首次指端溃疡到诊断SRC的时间显著延长。

要点

  • ERAs/PDE5i治疗未显著改变SSc-DU患者PAH或SRC的发生率。
  • 治疗组从首次指端溃疡至SRC诊断的时间较未治疗组显著延长。
  • 治疗组dcSSc亚型、抗拓扑异构酶I抗体及肌腱摩擦感更常见。

核心结论

  • ERAs/PDE5i治疗组与未治疗组之间PAH和SRC的发生率无差异。
  • 接受ERAs和/或PDE5i治疗似乎延迟了SRC的发生。

研究设计与样本

  • 回顾性队列研究,纳入西班牙硬皮病注册库(RESCLE)中系统性硬化伴指端溃疡(SSc-DU)患者。
  • RESCLE数据库1817例中544例(29.9%)有指端溃疡,221例(40.6%)接受ERAs/PDE5i治疗,323例(59.4%)未治疗。

主要发现

  • PAH发生率差异(95%CI)为-0.1(-4.8, 4.69),P=0.988。
  • SRC发生率差异(95%CI)为0.7(-2.2, 3.7),P=0.620。
  • 治疗组从首次指端溃疡到SRC诊断的时间为7.6(5.8)年,未治疗组为2.9(5.3)年,P=0.021。
  • 治疗组dcSSc亚型更常见(36% vs 26%,P=0.018),抗拓扑异构酶I抗体更常见(34% vs 18%,P<0.001),肌腱摩擦感更常见(12% vs 6%,P=0.038)。
  • 未治疗组lcSSc亚型更常见(57% vs 66%,P=0.031),ACA更常见(37% vs 46%,P=0.031)。

临床怎么用

  • 对于SSc-DU患者,ERAs/PDE5i治疗虽未降低PAH或SRC发生率,但可能延迟SRC发生。
  • 临床决策需结合SSc亚型、抗体状态及肌腱摩擦感等特征综合评估。

局限性

  • 回顾性队列研究设计可能存在混杂偏倚。
  • 治疗组与未治疗组基线特征存在差异(如dcSSc亚型、抗体分布)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i) are beneficial in pulmonary arterial hypertension (PAH) and digital ulcers (DU) and prevent from DU recurrences. Our study aimed to determine the difference in the incidence rate of PAH and scleroderma renal crisis (SRC) in patients with SSc and DU (SSc-DU) under ERAs/PDE5i or without treatment. METHODS: We conducted a retrospective cohort study including SSc-DU patients from the Spanish Scleroderma Registry (RESCLE). The primary outcome was the incidence rate of PAH and SRC in patients under ERAs/PDE5i or not. RESULTS: Some 544 patients out of 1817 (29.9%) in the RESCLE database had DU, 221 (40.6%) under ERAs/PDE5i and 323 (59.4%) not. The incidence rate (95% CI) difference between patients under treatment or not under did not reach statistical significance in PAH [-0.1 (-4.8, 4.69), P = 0.988] or in SRC [0.7 (-2.2, 3.7), P = 0.620]. However, the time from the first DU to the diagnosis of SRC was delayed in treated patients [mean (s.d.) 7.6 (5.8) years vs 2.9 (5.3); P = 0.021]. The dcSSc subset was more prevalent in the treatment group (36 vs 26%; P = 0.018), along with anti-topoisomerase I antibodies (34 vs 18%; P < 0.001) and tendon friction rubs (12 vs 6%; P = 0.038), whereas the lcSSc subset was more prevalent in the no-treatment group (57 vs 66%; P = 0.031) along with ACA (37 vs 46%; P = 0.031). CONCLUSION: There was no difference in the incidence rate of PAH and SRC between groups. However, treatment with ERAs and/or PDE5i appeared to delay the occurrence of SRC.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pestaña-Fernández M, Rubio-Rivas M, Tolosa-Vilella C, et al. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Rheumatology (Oxford). 2021. PMID: 32844220. doi:10.1093/rheumatology/keaa401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。